BRIDGEBIO REPORTS POSITIVE PHASE 3 RESULTS FOR SMALL MOLECULE BBP-418 IN LGMD2I/R9 FORTIFY STUDY
BRIDGEBIO: FORTIFY PHASE 3 STUDY MEETS ALL PRIMARY & SECONDARY INTERIM ANALYSIS ENDPOINTS
BRIDGEBIO: TO FILE NDA FOR APPROVAL WITH FDA IN H1 2026
Further company coverage: BBIO.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.